Suscripción a Biblioteca: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Publicado 6 números por año

ISSN Imprimir: 0743-4863

ISSN En Línea: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Pancreatic Cancer: Recent Advances in Nanoformulation-Based Therapies

Volumen 36, Edición 1, 2019, pp. 59-91
DOI: 10.1615/CritRevTherDrugCarrierSyst.2018025459
Get accessGet access

SINOPSIS

Pancreatic cancer is the fourth leading cause of death in the United States and has a 5-year life expectancy of ~8%. Currently, only a few drugs have been approved by the United States Food and Drug Administration for pancreatic cancer treatment. Despite available drug therapy and ongoing clinical investigations, the high prevalence and mortality associated with pancreatic cancer mean that there is an unmet chemopreventive and therapeutic need. From ongoing studies with various novel formulations, it is evident that the development of smart drug delivery systems will improve delivery of drug cargo to the pancreatic target site to ensure and enhance the therapeutic/chemoprevention efficacy of existing drugs and newly designed drugs in the future. With this in view, nanotechnology is emerging as a promising avenue to enhance drug delivery to the pancreas via both passive and active targeting mechanisms. Research in this field has grown extensively over the past decade, as is evident from available scientific literature. This review summarizes the recent advances that have brought nanotechnology-based formulations to the forefront of pancreatic cancer treatment.

CITADO POR
  1. Desai Preshita, Thakkar Arvind, Ann David, Wang Jeffrey, Prabhu Sunil, Loratadine self-microemulsifying drug delivery systems (SMEDDS) in combination with sulforaphane for the synergistic chemoprevention of pancreatic cancer, Drug Delivery and Translational Research, 9, 3, 2019. Crossref

  2. Etman Samar M., Abdallah Ossama Y., Elnaggar Yosra S.R., Novel fucoidan based bioactive targeted nanoparticles from Undaria Pinnatifida for treatment of pancreatic cancer, International Journal of Biological Macromolecules, 145, 2020. Crossref

  3. Tan Bee Ling, Norhaizan Mohd Esa, Curcumin Combination Chemotherapy: The Implication and Efficacy in Cancer, Molecules, 24, 14, 2019. Crossref

  4. Desai Preshita, Thumma Naga Jyothi, Wagh Pushkaraj Rajendra, Zhan Shuyu, Ann David, Wang Jeffrey, Prabhu Sunil, Cancer Chemoprevention Using Nanotechnology-Based Approaches, Frontiers in Pharmacology, 11, 2020. Crossref

  5. Desai Preshita, Wang Kevin Zhijun, Ann David, Wang Jeffrey, Prabhu Sunil, Efficacy and Pharmacokinetic Considerations of Loratadine Nanoformulations and its Combinations for Pancreatic Cancer Chemoprevention, Pharmaceutical Research, 37, 2, 2020. Crossref

  6. Hussain Arif, Hasan Anwarul, Babadaei Mohammad Mahdi Nejadi, Bloukh Samir Haj, Edis Zehra, Rasti Behnam, Sharifi Majid, Falahati Mojtaba, Application of gelatin nanoconjugates as potential internal stimuli-responsive platforms for cancer drug delivery, Journal of Molecular Liquids, 318, 2020. Crossref

  7. Demirtürk Nurbanu, Bilensoy Erem, Nanocarriers targeting the diseases of the pancreas, European Journal of Pharmaceutics and Biopharmaceutics, 170, 2022. Crossref

Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain